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Abstract 
In its more severe forms, COVID-19 progresses towards an excessive immune 
response, leading to the systemic overexpression of proinflammatory cytokines like IL6, 
mostly from the infected lungs. This cytokine storm can cause multiple organ damage 
and death. Consequently, there is a pressing need to identify therapies to treat and 
prevent severe symptoms during COVID-19. Based on previous clinical evidence, we 
hypothesized that inhibiting T cell co-stimulation by blocking CD80/86 could be an 
effective therapeutic strategy against progression to severe proinflammatory states. To 
support this hypothesis, we performed an analysis integrating blood transcriptional data 
we generated from rheumatoid arthritis patients treated with abatacept -a CD80/86 co-
stimulation inhibitor- with the pathological features associated with COVID-19, 
particularly in its more severe forms. We have found that many of the biological 
processes that have been consistently associated with COVID-19 pathology are 
reversed by CD80/86 co-stimulation inhibition, including the downregulation of IL6 
production. Also, analysis of previous transcriptional data from blood of SARS-CoV-
infected patients showed that the response to abatacept has a very high level of 
antagonism to that elicited by COVID-19. Finally, analyzing a recent single cell RNA-seq 
dataset from bronchoalveolar lavage fluid cells from COVID-19 patients, we found a 
significant correlation along the main elements of the C80/86 axis: CD86+/80+ antigen 
presenting cells, activated CD4+ T cells and IL6 production. Our in-silico study provides 
additional support to the hypothesis that blocking of the CD80/CD86 signaling axis may 
be protective of the excessive proinflammatory state associated with COVID-19 in the 
lungs. 
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Introduction 
 
Infection with SARS-CoV2 can lead to different degrees of symptomatology and severity, 
ranging from asymptomatic to an extreme immune response leading to patient death (1). 
The fatality rate of COVID-19 is estimated to be close to 1%, which is 10 times more 
than typical seasonal influenza (2). COVID-19 has been associated to the cytokine storm 
or cytokine release syndrome (CRS) (3), an overload of proinflammatory cytokines that 
leads to massive organ failure, predominantly uncontrollable lung inflammation that, 
even with the help of mechanical ventilation, can lead to organ collapse and death (4). 
Its high capacity of dissemination and the severity stages at which it can lead, have 
contributed to one of the largest pandemics since the Spanish flu in 1912 (5). There is 
currently a major international effort to develop vaccines against SARS-CoV2 (6). 
However, vaccine development is a lengthy process that needs to ensure both effective 
virus neutralization and patient safety(7). Therefore, while vaccines are being developed, 
there is a need to identify therapies that can help reduce the symptomatology associated 
with COVID-19 and, mostly, prevent infected individuals from progressing into life-
threatening stages(8).  
 
Many different strategies are being contemplated to find drugs to treat COVID-19. These 
include in-silico docking strategies (9), protein-protein network interactions (10)(11), in 
vitro testing (12), and also evaluation of disease progression to severe forms in patients 
undergoing different therapies. In inflammatory rheumatic disease, many patients are 
treated with drugs targeting specific components of the immune system (e.g. Tumor 
Necrosis Factor-alpha (TNF) and Interleukin-6 (IL6) signaling, and CD80/86 T cell co-
stimulation) to dampen the excess immune activation that characterizes these diseases. 
Closely evaluating these patients can provide invaluable information on how blocking 
certain elements of the immune response can be beneficial or detrimental towards 
COVID-19 severity. Using a cohort of 959 rheumatic patients under different targeted 
therapies, we have recently provided epidemiological evidence (13)  that suggests that 
anti-IL6 receptor therapy (tocilizumab) and CD80/86 blockade with CTLA4-Ig (abatacept) 
are associated with a lower prevalence of COVID-19 associated symptomatology as 
defined by the world health organization. Given that severe COVID-19 patients express 
high levels of IL6 (14), targeting the signaling of this cytokine -either directly or through 
its receptor- has been contemplated and is currently being used off-label to attempt to 
rescue critically ill patients (15). CTLA4-Ig, however, has not been so far proposed as a 
therapeutic agent for COVID-19 severity. Abatacept is a fusion protein consisting of the 
extracellular domain of human cytotoxic T lymphocyte antigen 4 (CTLA4) linked to the 
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modified Fc domain of human IgG1 (16). It binds to both costimulatory proteins CD80 
and CD86 on professional antigen presenting cells -dendritic cells, macrophages and B 
cells- with higher affinity than CD28 on the surface of T cells, thereby preventing the 
necessary costimulatory signal required by T cells to progress to activation. It was 
originally developed to treat rheumatoid arthritis, where T cell activation is central to the 
disease pathology, but has currently been approved also for psoriatic arthritis and 
juvenile idiopathic arthritis (16).  
 
In severe COVID-19, macrophages in the lung activate and produce large amounts of 
IL6. Single cell analysis on bronchoalveolar lavage fluid (BALF) from COVID-19 patients 
suggest that monocyte-derived FCN1+ macrophages substitute alveolar macrophages 
in the lung during inflammation (17). In either case, how macrophages drastically 
increase the proinflammatory levels in COVID-19 is yet not known(8). High levels of T-
cell mediated activation could be one of the possible causes. In turn, T cells could 
become hyperactivated due to excessive activation through the CD80/86 axis (Figure 
1). Therefore, dampening this activation signaling pathway could be an effective 
therapeutic approach to prevent immune system hyperactivation, and progress to more 
severe stages. To support this hypothesis raised by the findings of our previous 
epidemiological survey in rheumatic patients, here we performed an in-silico study using 
transcriptional data from abatacept-treated patients as well as from COVID-19 patients. 
Our data support a significant antagonism of abatacept on COVID-19-associated 
processes at the systemic level, and suggest that blocking the CD80/86 axis could be a 
useful therapeutic approach to reduce the level of macrophage-associated inflammatory 
response.   
 
 
Methods 
 
Patients and samples 
 
A total of n=38 rheumatoid arthritis (RA) patients starting treatment with abatacept were 
recruited in the framework of the PACTABA project (BMS). All patients were treated with 
subcutaneous abatacept at the recommended weekly dosage of 125 mg. The PACTABA 
project is a multicentric Spanish pharmacogenomic study performed in a subset of 
patients from the ASCORE clinical trial (Bristol-Myers Squibb, ClinicalTrials.gov 
Identifier: NCT02090556). This observational and prospective study was designed to 
estimate the retention rate of subcutaneous abatacept over 24 months in the routine 
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clinical practice of RA patients (18). The study was approved by the institutional review 
board and informed consent was obtained in all cases. 
 
Whole blood samples were obtained at the start of the therapy with abatacept and at 
week 12. Blood was collected using RNA-stabilizing PaxGene tubes (PreAnalytiX, 
Switzerland), which preserve total RNA from the time of venipuncture. Total RNA was 
extracted using the PaxGene blood isolation kit (Qiagen). All samples had a RIN index 
> 7 and were included for RNA-seq analysis. RNA-seq libraries were performed using 
with the KAPA RNA HyperPrep Kit, with RiboErase (HMR) Globin (globin and rRNA 
depletion protocol) for Illumina sequencing platforms and with the addition of Unique 
Molecule Identifiers (UMIs). Sequencing was performed using the NovaSeq platform 
(Illumina) at average of 250 paired-end reads.  
 
RNA data preprocessing 
 
For our RA patient cohort, FASTQ files were aligned to the GRCh37 human reference 
genome assembly using STAR (19). After alignment, we performed deduplication of the 
PCR duplicates using UMItools (20) to mark and after removing with samtools (21). 
Gene-level read counts of the deduplicated bam files were obtained with featureCounts 
(22). The RA longitudinal dataset will be made available through the NCBI Gene 
Expression Omnibus database (GEO link available after data has been deposited). 
 
To characterize the gene expression profile associated with COVID-19, the RNA-seq 
data from Xiong et al on peripheral blood mononuclear cells (PBMCs) from three patients 
infected with COVID-19 and three healthy controls was  used (23). The raw sequencing 
data was processed as described previously. In order to infer the purity and cell 
composition of this dataset, we used the ABIS immune cell deconvolution method which 
has been specifically developed for PBMC data (24). This analysis revealed potential 
neutrophil presence, particularly in one sample (Supplementary Figure 1). To 
compensate for this potential confounding effect, the estimated percentage of 
granulocytes was used as a covariate in the differential expression analysis.  
 
Differential expression and gene set enrichment analysis 
Genes differentially expressed in COVID-19 patients were determined using edgeR (25). 
Raw counts were normalized by trimmed mean of mean values (TMM) normalization, 
and genes with low expression values (i.e. < 2 counts per million -CPM- in at least 2 
samples). Differentially expressed genes were determined by fitting a quasi-likelihood 
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negative binomial generalized linear model and adjusting for multiple testing by 
Benjamini & Hochberg (26). Genes with an adjusted p-value < 0.05 were considered 
significant.   
 
To test for gene expression changes induced by treatment with abatacept at a systemic 
level, the differential expression between baseline and week 12 was tested in RA 
patients using limma (27). Raw counts were normalized using TMM normalization for all 
genes with > 0.6 CPM in at least 20 samples. Normalized counts were log-transformed 
to log-counts using voom (28) and a linear model was fitted blocking by individual and 
adding sex, age and batch (i.e. library plate) as covariates. The percentage of 
granulocytes in each sample were estimated using DeconCell (29), and also included as 
a covariate in the model in order to make the results more directly comparable with the 
results obtained with the COVID-19 dataset. 
 
Biological processes affected either by SARS-CoV-2 infection or treatment with 
abatacept were determined using the Gene Set Enrichment Analysis (GSEA)(30) 
implemented in the fGSEA R package. To rank the genes based on their association to 
COVID-19 and abatacept, the minus log of the p-value of the differential expression 
analysis was calculated and multiplied by the sign of the log fold change as described 
previously (31). We included the sign of the log fold change in order to preserve the 
directionality of the enrichment and, therefore, to be able to determine if the biological 
process was either activated or repressed by the viral infection and by the treatment with 
abatacept. Biological processes with a FDR < 0.05 and a normalized enrichment score 
(NES) > 0 were considered to be up regulated, while biological processes with a FDR < 
0.05 and a NES < 0 were considered to be down regulated. 
 
Analysis of the antagonism of the abatacept signature to COVID-19 associated 
processes 
To identify COVID-19 biological processes we used two alternative strategies. In the first, 
we identified a list of biological processes that have been associated to COVID-19 
pathology through diverse clinical and biological studies. In particular, biological 
processes that have been associated with COVID-19 severity were prioritized. Those 
pathological processes that were unlikely to be captured at the blood transcriptional level 
(e.g. lung fibrosis) were excluded. A total of 22 processes were finally selected, which 
are divided in a group of 6 processes related to viral immune sensing and anti-viral 
response (i.e. first stage of COVID-19)(5), and a group of 16 processes related to 
hyperinflammation and severity (i.e. second stage)(32)(3)(33)(34). Table 1 describes the 
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selected processes and the most relevant bibliographical evidence. To evaluate their 
modulation by abatacept, we selected a representative gene set from the Biological 
Process (BP) database from the Gene Ontology (GO)(35) and tested their association 
to treatment with GSEA as described previously. 
 
In the second approach, we used the available PBMC transcriptional data generated 
from COVID-19 patients and controls (14) to determine the biological processes 
associated with COVID-19. Similarly, biological processes regulated by abatacept at the 
systemic level were determined by comparing the baseline gene expression of RA 
patients to the expression after 12 weeks of treatment with abatacept. To avoid testing 
BPs represented by very low gene numbers or excessive gene content (too broad 
process annotation), we selected only GO terms with > 10 genes and < 300 genes. To 
account for the large number of GO terms tested, a false-discovery rate (FDR) 
adjustment was performed. GO terms with FDR < 0.05 were considered significant. 
Since many GO terms can be very similar in their gene composition, we reduced the 
redundancy in the analyzed gene sets using a distance measure based on the Jaccard 
index and hierarchical clustering. Within each cluster, the GO term showing the highest 
association to COVID was chosen to represent the corresponding biological process. 
 
Single cell RNA-seq analysis of COVID-19 BALF cells 
In order to evaluate the potential utility of CTLA4-Ig blockade of CD80/86 T cell signaling 
in COVID-19-mediated lung inflammation, we analyzed single cell RNA-seq data from 
bronchoalveolar lavage fluid (BALF) cells. Single-cell RNA-seq raw data from BALF 
samples from 9 COVID-19 patients (n=6 severe and n=3 mild) and 3 controls were 
downloaded from the GEO database (accession GSE145926). This dataset was 
generated using the 10x genomics platform and includes samples used in a publication 
demonstrating the predominant influx of monocyte-derived macrophages in COVID-19 
patients (17). The raw data processing and analysis -including, normalization, scaling, 
and clustering of cells- was performed using Seurat (v3)(36)(37) and scTransform (38). 
Cells with <200 or >6,000 unique feature counts, >10% mitochondrial counts or < 1,000 
UMIs were filtered out. Samples were log-normalized and scaled for the number of 
genes, number of UMIs and percentage of mitochondrial reads. Cell type clustering was 
performed using the “FindClusters” function from Seurat. In brief, this method uses a 
shared nearest neighbour (SNN) modularity optimization-based clustering algorithm to 
identify clusters of cells based on their PCs. Before constructing the SNN graph, this 
function calculates the k-nearest neighbours. The number of PCs used for each 
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clustering round (k=50) was estimated by the evaluation of the elbow of the PCA scree 
plot. 
 
Results 
The transcriptional changes induced by CD80/86 blocking antagonize COVID-19 
associated processes 
In our first approach, we evaluated how COVID-19 pathological processes were affected 
by treatment with CTLA4-Ig at the transcriptional level. Of the 22 curated processes, we 
found that abatacept induced transcriptional changes in 16 of them (72.7%, binomial test 
P=8.5e-17). All significant changes occurred in the opposite direction to that described 
by previous clinical and experimental studies on COVID-19 Figures 2A and 2B show 
the observed changes induced by CTLA4-Ig in the anti-viral primary response and 
hyperinflammation biological processes, respectively. Figures 3A and 3B show a 
detailed visualization of the differential gene expression for the selected pathological 
processes representing anti-viral immune response and hyperinflammation-mediated 
severity, respectively.  
 
In our second approach, we identified a total of 260 pathways differentially activated in 
COVID-19 patients compared to controls (FDR < 0.05) (Supplementary Table 1). These 
pathways were mostly associated to phagocytosis, endocytosis and lysosome function, 
immunoglobulin mediated immunity, antigen processing and presentation, acute 
inflammatory response and cytokine cascades (i.e. IL1, IL6 and IL8 production, TNF 
signaling, type I and type II interferon signaling, NF-kB signaling and macrophage 
activation), metabolic processes, mitochondrial activity, cell cycle, response to reactive 
oxygen species and apoptosis. Other interesting pathways included the down-regulation 
of T cell receptor signaling, the over-activation of the cellular response to angiotensin, 
the up regulation of transferrin transport and the regulation of blood pressure. 
 
In the RA patient cohort, comparing week 12 to baseline gene expression profiles, we 
found 109 pathways associated with CTLA4-Ig therapy (FDR < 0.05, Supplementary 
Table 2). These pathways were associated predominantly to cell cycle and cell division, 
myeloid cell differentiation, antigen processing and presentation, immunoglobulin 
mediated immunity, acute inflammatory response, cytokine cascades (IL7 and IL6), 
phagocytosis, endocytosis and lysosome function, ribosomal RNA related processes 
and apoptosis. Comparing the two datasets, we found a total of 49 overlapping significant 
pathways (Figure 4). From these, 47 (96%) were found to be antagonistically activated 
by abatacept compared to COVID-19. Among the significant antagonistic processes, we 
 8 
found 16 pathways related to immune system processes including processes related to 
viral defense (viral transcription, GO:0019083), innate immune system activation (Fc 
receptor signaling pathway, GO:0038093; myeloid leukocyte differentiation: 
GO:0002573) and acquired immune response (regulation of B cell activation, 
GO:0050864;  humoral immune response mediated by circulating immunoglobulin, 
GO:0002455) and cytokine production (interleukin-6 production; GO:0032635). Other 
abundant significant processes included those related with cell cycle and RNA 
transcription (n=18) and with endocytosis (n=5). Only one pathway (mitochondrial 
translational elongation, GO:0070125) was activated and one process (mucosal immune 
response: GO:0002385) was inactivated by both exposures. The probability that the 
observed antagonism occurred by chance, is very low (P value < 2.5e-18, binomial test). 
Figure 5 shows the most significant processes antagonized by CD80/86 blocking with 
abatacept. The complete list of overlapping -antagonistic and agonistic- pathways is 
included in Supplementary Table 3.   
 
scRNA-seq analysis of CD80/86 axis in BALF 
In order to evaluate the relevance of CD80/86 co-stimulation in COVID-19 pathology we 
analyzed the correlation of three key cell types participating in this axis: CD80+ or CD86+ 
antigen-presenting cells, activated CD4+ T cells and IL6-producing macrophages. For 
this objective we analyzed a recent scRNA-seq dataset generated from 12 BALF 
samples (17).This dataset consists on samples from six severe and three moderate 
COVID-19 patients, as well as a set of CD45+ selected BALF cells from healthy controls. 
In total, 54,420 cells passed our quality control analysis and were analyzed using the 
scTransform algorithm (38). With this approach a total of 34 cell clusters were identified 
(Figure 6).  
 
Most of the cell clusters aggregated into four major regions representing i) T and NK 
cells (8,014 cells, 14.7%, clusters 9, 11, 5, 25 and 18), ii) two regions of FABP4+ alveolar 
macrophage cells (17,399 cells, 32%, clusters 1, 2, 3, 30, 7, 32 and 12), and iii) a large 
cluster aggregate of active, IL6-expressing macrophages both from FABP4+ alveolar  
and monocyte-derived FCN1+ macrophages (24,742 cells, 45.5%, clusters 6, 20, 13, 22, 
0, 8, 4, 15, 10, 16, 14, 26). Both alveolar macrophage-only clusters belong to the three 
healthy controls (Supplementary Figure 2). As described by the original study(17), 
there is a marked transition from FABP4+ alveolar macrophages to FCN1+ monocyte-
derived macrophages from healthy to infected, and as COVID-19 severity increases 
(Figure 7 A).  
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When looking at the co-stimulation proteins that are the target of CTLA4-Ig -CD80 and 
CD86- we found that healthy controls had a significantly lower expression of both 
proteins (Figure 7 B). This difference was high for CD86 (26.5% CD86+ in controls vs 
45.4% in COVID-19 infected patients, P<1e-16) and drastically different for CD80+ cells 
(1.7% CD86+ in controls vs 19.6% in COVID-19 infected patients, P<1e-16). Next, we 
identified the set of cells showing production of IL6, the key cytokine in COVID-19 
severity and the cytokine storm. Among the different BALF cell clusters, we found IL6-
expressing cells almost exclusively in the activated macrophage cluster derived from 
COVID19 patients (Figure 7 C). Finally, we identified the cluster containing the CD4+ T 
cell element of the CD80/86 axis. Cluster 5 was found to aggregate markers of different 
types of CD4+ T cells including CCR7 (naïve TCD4), IL2RA (Treg), FOXP3 (Treg), IL7R 
(naive), LTB (naive), CXCL13(T peripheral helper) (Figure 7D). This cell cluster also was 
characterized by the expression of CTLA4, the protein that is recombined in abatacept 
and also a marker that is highly upregulated in active T cells and Treg cells (39), and 
was therefore used to represent the CD80/CD86 activated T CD4+ element.  
We next tested for association between the simultaneous presence of each element, of 
the CD80/86 axis. First, we found a significant correlation between CD80+ or CD86+ 
APCs and active CD4+ T cells (r2=0.87, P=0.00036; and r2=0.73, P=0.0069) (Figure 8A 
and Figure 8B). Second, we also found evidence of correlation (r2=0.79, P=0.0024) 
between the number of activated CD4+ T cells and the number of IL6 producing cells 
(Figure 8C). Finally, we found a significant correlation between the number of CD80+ or 
CD86+ cells and IL6+ production (r2=0.93, P=1.5e-7, and r2=0.82, P=0.0011, 
respectively) (Figure 8D). 
 
 
Discussion 
Since the beginning of the pandemic, SarsCov-2 has infected >4 million people and 
caused at least 280,000 deaths world-wide as of May 11th 2020 
(https://coronavirus.jhu.edu/map.html). There is currently a pressing need to identify 
therapies that can help prevent and treat patients with more severe symptoms of COVID-
19. Based on previous epidemiological evidence from rheumatic treated patients on 
several targeted immunomodulators, we have found evidence that CTLA4-Ig (abatacept) 
could be protective of COVID-19 symptomatology. Here we provide additional in-silico 
evidence to support the link between the relevance of the CD80/86 axis and COVID-19. 
We have characterized the transcriptional response of abatacept-treated RA patients 
and we have found that is highly antagonistic to key biological processes that have been 
linked to COVID-19 severity. Using gene expression data from COVID-19 infected 
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patients, we have also found that this antagonism extends significantly to many other 
biological processes induced by SARS-CoV2 virus infection. Finally, analyzing single cell 
data from BALF samples, we have found evidence that the CD80/86 axis is closely linked 
to IL6 expression in the BALF macrophage compartment in COVID-19.  
 
Our results suggest that blocking the CD80/86 axis could be useful to dampen the 
hyperactivation of the immune response in severe COVID-19, and subsequently reduce 
the damage to the lungs and the excessive systemic cytokine production. Once SARS-
CoV2 enters the lung through attachment to ACE2 expressed on alveolar epithelial cells 
(40)(41), an immune response is subsequently mounted. Central to this response, 
phagocytic cells, initially alveolar macrophages that are eventually replaced by massively 
infiltrating monocytes (17), are highly activated, releasing a large number of cytokines. 
Macrophages act as powerful antigen-presenting cells (APCs) on activated CD4+ T cells 
to further amplify the level of immune response. For this objective, the co-stimulatory 
signal in the form of CD80 and CD86 expression in the surface of APCs is essential, 
otherwise an anergic program is initiated (42). From all organs, the lung is the tissue with 
the highest levels of CD80 mRNA, and the second tissue after the spleen with the highest 
levels of CD86 mRNA expression (Supplementary Figure 3). Even CTLA4 itself is 
highly expressed in the lung compared to the rest of tissues. This high expression of the 
elements of the CD80/86 axis might reflect the need of the lung to respond rapidly to 
potential immunological insults in a tissue that is constantly exposed to environmental 
cues (43). However, having this natively high potential for antigen presentation and T 
cell activation could be a detrimental factor in a rapidly spreading virus like SARS-CoV2. 
A larger cell mass capable of activating T cells would in turn lead to a more pronounced 
stimulation of IL6 producing programs (44). This high signal amplification potential could 
therefore explain the sudden transition into the extremely high cytokine production stage 
known as cytokine storm (45).   
 
In our analysis approach, treatment with CTLA4-Ig showed a regulation at the 
transcriptional level that is highly antagonistic to that induced by COVID-19. We have 
shown this by two complementary strategies. In the first strategy we have found that, 
from the most well-established pathological processes associated with COVID-19 to 
date, abatacept induces a transcriptional change that is contrary to the one induced by 
the virus in most of them. In a first group of processes related to innate immune system 
detection of SARS-CoV2 we found that treatment with abatacept downregulates TLR-
signaling pathway and endosomal transport. TLRs are key to detect the presence of the 
virus, leading to the activation of proinflammatory transcription factors and the 
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expression of IFN and other cytokines(46). While viral detection is essential to trigger the 
immune response in the first stages of the infection, later its utility might be superseded 
by the need to adequately control excessive inflammatory response (5). To this regard, 
our analysis did not detect a strong type I IFN inhibition, thereby suggesting that this 
basic anti-viral mechanism is protected. Of interest, we found a significant 
downregulation of endosomal transport, a biological process that has been linked to the 
possible protective of hydroxychloroquine in COVID-19 (33). A reduction endosomal 
development and maturation would keep at stake viral load. However, the confirmation 
of this mechanism in relation to SARS-CoV2 infection and the clinical protection are still 
controversial and are in need of robust evidence (47).  
 
Abatacept inhibits many biological pathways that are key to the hyperinflammatory stage. 
As described previously, the immune response to SARS-CoV2 can be divided into two 
phases, one first phase where the antiviral response is deployed and a second phase of 
excessive inflammatory response (27). The latter might not activate in many infected 
patients, but likely occurs in most of those who progress to more severe symptoms, 
particularly those with increasing lung inflammation. This stage is characterized by the 
activation of myeloid cells, mostly monocyte-derived macrophages that massively 
infiltrate the lung (8). We have found that treatment with CTLA4-Ig significantly down-
regulates myeloid leukocyte differentiation and macrophage activation. This specific anti-
inflammatory role could be a useful property to avoid entering into the life-threatening 
massive cytokine release stage. To this regard, we have found that abatacept 
downregulated both the production and the response to several key cytokines of the 
severe stage in COVID-19 including TNF (48), IL1 (33), IL8 (49), IL7 (48) and IL6 (48). 
Importantly, we have found that downregulation is strong for IL6, the cytokine that is 
more abundantly produced in patients progressing to severity both in serum and in the 
lungs (45). Therapies aimed at IL6 signaling, tocilizumab and sarilumab, are currently 
being evaluated in at least three clinical trials by 11th May 2020, and there is increasing 
reporting of beneficial effects in off-label use in severe patients (50). In line with this, our 
previous epidemiological study, both CD80/86 blocking and anti-IL6R therapies showed 
the lowest incidence of COVID-19 suspected cases among rheumatic patients (13). 
Consequently, the potential beneficial effect of CTLA4-Ig could be due to the upstream 
regulatory effect of this central cytokine for COVID-19 pathogenesis. 
 
Abatacept also strongly downregulated two additional immune processes: complement 
activation and B cell mediated immunity. Complement over-activation has been identified 
in the lungs of COVID-19 and antibody therapies against elements of the complement 
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system are being currently being evaluated to treat severe cases (32). The 
downregulation of the B cell mediated response, could also be beneficial to avoid 
overactivation of the myeloid compartment. While neutralizing antibodies to SARS-CoV 
are associated to a reduction in the viral load (51), there is also the possibility that high 
titers antibodies could lead to a more aggressive immunological response. During the 
SARS-CoV1 epidemic, neutralizing antibody levels were higher in deceased patients 
(52), which raised the possibility of antibody-dependent enhancement (ADE) contributing 
to disease exacerbation. In this situation, non-neutralizing antibodies facilitate the 
phagocytosis of the virus into macrophage through the Fc-receptor leading to their 
activation into proinflammatory phenotypes (53). ADE has been previously identified in 
other coronaviruses (54)(55), and experimental evidence in rhesus macaques infected 
with SARS-CoV1 found that anti-spike IgG antibodies contributed to massive influx of 
monocytes in the lung and subsequent severe acute injury (56). In this context, the effect 
of reducing B cell immunity by abatacept might be beneficial by reducing the likelihood 
of low-affinity antibodies that would contribute to ADE-induction (7). To this regard, 
evidence showing that antibodies raised against SARS-Cov2 can lead to ADE would be 
of high relevance, particularly in the development of safe vaccines.    
 
The results of this study are entirely in the in-silico domain and therefore they must be 
considered as additional evidence on top of increasing evidence from the clinical domain. 
Consequently, additional independent data from large patient cohorts will be useful to 
confirm this hypothesis. For example, the Global Rheumatology Alliance (57), an 
international collaborative initiative that is currently aggregating data from patients 
around the world, will likely become an ideal resource to confirm the observed lower at-
risk incidence in abatacept-treated rheumatic patients (13). Among the limitations of this 
study is that our analysis of transcriptional changes due to abatacept could have been 
confounded by the specific immune activation that is due to RA. Like SARS, however, 
RA is a disease where macrophage IL6 production is central to the pathology (58). Of 
relevance, there is increasing evidence that abatacept could be an efficacious therapy 
to treat interstitial lung disease in RA (ILD) (59). ILD is a comorbidity that occurs in RA 
patients and is characterized by the inflammation and subsequent fibrotic development 
of the lung tissue. Treatment with abatacept was motivated by the finding that blocking 
T cell co-stimulation through CTLA4-Ig is effective in a mouse model of hypersensitivity 
pneumonitis (60), a disease characterized by a massive influx of activated T cells in the 
lungs and where alveolar macrophages express high levels of B7 (CD80/CD86) 
molecules. This evidence is in line with our hypothesis that the CD80/86 axis is a key 
factor for lung hyperinflammatory response. Additionally, while immunosuppressive 
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agents are generally associated with an increase in the risk of infectious diseases in 
rheumatic patients (61), abatacept has shown to be the therapy that least increases this 
risk. There is substantial epidemiological evidence supporting that abatacept-treated 
patients do not increase the risk of serious infections (62)(63)(64).  
 
Our finding that abatacept-treated patients have a lower percentage of COVID-19 
symptoms, prompted us to provide additional evidence of the benefit of this therapeutic 
approach. After characterizing the transcriptional changes induced by the therapy in a 
cohort of RA patients, we have seen that it is highly antagonistic to that induced by 
COVID-19, both to several of the most well-known pathological processes associated 
with the disease, and to the biological processes that are differentially activated in 
samples of patients. Together, this evidence identifies blocking of the CD80/86 axis as 
a candidate therapy for COVID-19. To this regard, Belatacept, a CTLA4-Ig drug derived 
from abatacept that binds more avidly to CD80/86 and is used to prevent renal transplant 
rejection (65), could be a therapeutic alternative. However, there’s yet no epidemiological 
evidence evaluating this drug in relation to COVID-19, with only sporadic reporting (66). 
While the development of vaccines and the questions like permanency of immunization 
are still being investigated, there is a need to find therapies that can lower the risk of 
progressing to severe stages of COVID-19 and reduce the number of fatalities during 
the next months or years. Additional clinical and experimental evidence gathered in the 
next months will be crucial to confirm if blocking of the CD80/86 axis is a useful 
therapeutic approach to prevent progression to severe stages of the disease. 
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Data and code availability 
The whole code used to analyze the PBMC RNA-Seq data from COVID-19 infected 
patients, blood RNA-Seq data from RA patients treated with abatacept and the BALF 
single-cell RNA-Seq dataset is freely available at https://github.com/Rheumatology-
Research-Group/COVID-19_Abatacept. The dataset generated during this study will be 
deposited in the Gene Expression Omnibus (GEO) repository. 
 
 
 
Figure Legends 
 
Figure 1. CTLA4-Ig (abatacept) dampens T cell co-stimulation and excessive 
cytokine production in COVID-19. Schematics depicting the model for abatacept-
mediated inhibition of excess cytokine production. Once lungs become infected with 
SARS-CoV2 virus, an immune response is mounted. Antigen presenting cells (APCs) in 
the lung present antigen to activated CD4+ T cells thereby stimulating their production 
of proinflammatory cytokines (e.g. TNF, IL6). Resident alveolar macrophages and, 
mostly, large numbers of infiltrating monocyte-derived macrophages respond to the T 
cell stimulation by producing large quantities of interleukins, mainly IL6. Large numbers 
of activated macrophages present in the lung can lead to systemic secretion of IL6, 
forming the cytokine storm. Treatment with CTLA4-Ig recombinant fusion protein could 
dampen APC activation of T cells and, therefore, reduce the level of hyperinflammatory 
response observed in severe COVID-16 patients. 
 
Figure 2. Longitudinal transcriptional changes induced by CTLA4-Ig therapy in 
COVID-19 associated processes. A. Changes in biological processes associated with 
immune viral response. B. Changes in biological processes associated with 
hyperinflammation and severity in COVID-19. The first column on the left indicates the 
direction of change of the biological process by COVID19 as described in different clinical 
and experimental studies (blue: up-regulation, red: down-regulation). As a reference, we 
include the transcriptional changes observed for the same set of processes in the 
COVID-19 PBMC samples (middle column). Finally, the third column shows the change 
induced by treatment with abatacept in RA patients. Up-regulation (blue) and down-
regulation (red) is depicted according to effect size (diameter of circle). Statistical 
significance is reflected as color intensity and p-value levels according to *<0.05, 
**<0.005, ***<0.0005, ****<0.00005 and *****<0.000005.  
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Figure 3. Gene-level differential expression of the COVID-19 related biological 
processes induced by abatacept. A. Immune sensing and response to viral infection. 
B. Immune processes associated with COVID-19 severity stages. Volcano-plots showing 
the statistical significance (-log10(p-value), y-axis) against the effect size (log fold 
change, x-axis) for all genes. In color are highlighted the genes from the specific 
biological processes, red for genes down-regulated by abatacept, and blue for genes up-
regulated by abatacept.  
 
Figure 4. Venn plot of the biological processes regulated by COVID-19 and by 
abatacept. Numbers represent the biological processes that are specific and those that 
are commonly changed by both exposures. From the latter, 47 processes modified by 
COVID-19 are antagonistically modified by abatacept, compared to only 2 processes 
that are agonistically induced by co-stimulation inhibition.  
 
Figure 5. Most significant COVID-19 transcriptional processes antagonized by 
abatacept. The 20 top biological processes more significantly down or up-regulated by 
COVID-19 at the transcriptional level and also more significantly antagonized by 
abatacept are shown in this diagram. Up-regulation (blue) and down-regulation (red) is 
depicted according to effect size (diameter of circle). Statistical significance is reflected 
as color intensity and p-value levels according to *<0.05, **<0.005, ***<0.0005, 
****<0.00005 and *****<0.000005. 
 
Figure 6. UMAP of the BALF samples from COVID-19 and healthy control 
individuals. Total cell BALF samples from 6 severe and 3 mild COVID-19 infected 
individuals and 3 CD45+ sorted BALF samples from 3 healthy controls were analyzed 
for cell cluster identification. Each number depicts each of the 34 cell clusters identified 
using the SNN approach implemented in Seurat v3. 
 
Figure 7. Expression of cell type specific markers in BALF samples from COVID-
19 and healthy controls. 2-Dimensional visualization of gene expression based on the 
identified cell clusters (Figure 6). A. Previously described markers FCN1+ and FABP4+ 
defining monocyte-derived macrophages and resident alveolar macrophages, 
respectively. The two cluster aggregates that entirely express FABP4 correspond of cells 
from healthy controls. B. Expression of co-stimulating protein genes CD80 and CD86, 
which are the target of abatacept. While CD86 has a more ubiquitous expression 
(including both FCN1+ and FABP4+ macrophages), CD80 is specifically expressed in 
FCN1+ monocyte-derived macrophages. C. IL6 expression is circumscribed to the 
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activated macrophage cluster. D. Selected T cell markers representing activated T cells 
(CTLA4, IL2RA), CD8+ lymphocytes (CD8A) and Tregs (FOXP3 and IL2RA). CTLA4 
expression is enriched in the CD4+ T cell cluster 5. 
 
Figure 8. CD80/86 axis cell type abundance and correlation. Scatter plots showing 
the cell type abundance correlation between the key elements of the CD80/86 axis 
targeted by CTLA4-Ig therapy. All pairwise correlation analyses were found to be positive 
and significant (r2 > 0.7, P<0.005). A CD86+ cells vs active CD4+ T cells. B CD80+ cells 
vs active CD4+ T cells. C active CD4+ T cells vs IL6+ cells. D CD86+ cells vs IL6+ cells. 
E CD80+ cells vs IL6+ cells.  
 
 
Supplementary Figure Legends 
 
Supplementary Figure 1.  Evidence of neutrophil presence in the COVID-19 PBMC 
dataset. Using the cell type deconvolution approach in ABIS, we identified a potential 
presence of neutrophils in the PBMC samples. In order to correct for this potential 
confounder, we used the estimated neutrophil percentage as covariate in the differential 
expression analysis. N1-3: control samples; P1-P3: patient samples.   
 
Supplementary Figure 2.  UMAP depicting the individual origin of the cell clusters. 
Cell coloring is based on the 12 individuals simultaneously analyzed in the BALF scRNA-
Seq study. Samples C51, C52 and C100 correspond to the three controls, which clearly 
show distinct clusters of FABP4+ alveolar macrophage cells. The remaining samples are 
from COVID-19 patients with 3 samples from mild patients (C141, C142 and C144) and 
6 samples from patients with severe disease (C143, C145, C146, C148, C149, C152). 
 
Supplementary Figure 3.  Tissue-level gene expression distribution for CD80, 
CD86 and CTLA4 genes from GTex database. The distribution of gene expression 
levels for the three key genes from 53 human tissues from nearly 1,000 individuals are 
shown (GTex database, version 8). All three key genes from the CD80/86 axis are highly 
expressed in the lung, being the first tissue for CD80, the second for CD86 and the third 
for CTLA4 mRNAs.  
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Table 1. List of biological processes associated with COVID-19 pathology 
 
Biological process GO term Implication in SARS-CoV-2 References 
Viral entry into cell endosomal transport Mechanism of viral entry into cell. (33)(67) 
Virus sensing toll−like receptor signaling pathway 
Dificultates cell infection. Evaded 
by CoVs. (33) 
Virus sensing 
cytoplasmic pattern recognition 
receptor signaling pathway in 
response to virus 
Dificultates cell infection. Evaded 
by CoVs. (33) 
Virus sensing type I interferon signaling pathway Unclear. Impaired in severe. (68)(5)(69) 
Natural killer mediated immunity natural killer cell chemotaxis Over-activation (17)(15) 
Natural killer mediated immunity 
natural killer cell mediated 
cytotoxicity Down-regulated (70)(71) 
Blood coagulation regulation of blood coagulation Up regulated in severe. (72)(73) 
    
Biological process GO term Implication in SARS-CoV-2 References 
T cells T cell mediated immunity 
Blood lymphopenia, altered 
function, activated and exhausted 
in severe. Increased in lung. (8)(74)(74)(70)(75)(76)(77)(78)(79)(80)(17)(81) 
T cells T cell cytokine production Over activation. Up in severe. (8)(74)(80)(17)(81) 
T cell interaction with myeloid cells antigen processing and presentation Up in severe (44) 
T cell interaction with myeloid cells response to interferon−gamma Over activation (48)(8)(82) 
T cell interaction with myeloid cells 
cellular response to tumor necrosis 
factor Over activation (8) 
Myeloid cell activation myeloid leukocyte differentiation Over activation. Up in severe. (8)(74)(83)(76)(84)(17) 
Myeloid cell activation macrophage activation Over activation. Up in severe. (8)(74)(83)(76)(17)(73) 
Cytokine production interleukin−1 production Over activation (48)(76)(81) 
Cytokine production interleukin−6 production Over activation. Up in severe. (49)(8)(75)(69)(83)(84)(77)(73)(82) 
 36 
Cytokine production tumor necrosis factor production Over activation. Up in severe. (48)(49)(8)(75)(69)(83)(22)(73) 
Cytokine production interleukin−8 production Over activation. Up in severe. (48)(49)(75)(73) 
Cytokine production response to interleukin−7 Over activation. Up in severe. (48)(8) 
Cytokine production interleukin−10 production Over activation. Up in severe. (48)(49)(75)(77)(82) 
Complement pathway complement activation 
Over activation in lung. Up in 
severe. (32) 
Ig production by B cells B cell mediated immunity Over activation. Up in severe. (33)(51)(52)(80) 
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Suppl. Fig. 3 
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Supplementary Table 1: List of biological processes associated to COVID-19 infection.
ID Description Size NES pvalue p.adjust ratio
GO:0016236 macroautophagy 295 2.152 1.96E-06 1.08E-04 0.432
GO:0038093 Fc receptor signaling pathway 241 2.466 1.96E-06 1.08E-04 0.524
GO:0002758 innate immune response-activating signal transduction 298 1.895 1.96E-06 1.08E-04 0.414
GO:0015980 energy derivation by oxidation of organic compounds 285 2.125 1.96E-06 1.08E-04 0.330
GO:0002440 production of molecular mediator of immune response 286 1.918 1.96E-06 1.08E-04 0.442
GO:0072593 reactive oxygen species metabolic process 284 1.975 1.97E-06 1.08E-04 0.455
GO:0019882 antigen processing and presentation 226 2.494 1.97E-06 1.08E-04 0.475
GO:0006733 oxidoreduction coenzyme metabolic process 207 2.138 1.97E-06 1.08E-04 0.468
GO:0002455 humoral immune response mediated by circulating immunoglobulin 150 3.043 1.97E-06 1.08E-04 0.739
GO:0030100 regulation of endocytosis 281 1.998 1.97E-06 1.08E-04 0.477
GO:0036294 cellular response to decreased oxygen levels 217 1.995 1.97E-06 1.08E-04 0.439
GO:0046434 organophosphate catabolic process 248 2.072 1.97E-06 1.08E-04 0.351
GO:0016052 carbohydrate catabolic process 199 2.129 1.97E-06 1.08E-04 0.393
GO:0010324 membrane invagination 135 2.441 1.97E-06 1.08E-04 0.701
GO:0022900 electron transport chain 186 2.139 1.97E-06 1.08E-04 0.577
GO:0016054 organic acid catabolic process 275 1.950 1.97E-06 1.08E-04 0.465
GO:0033209 tumor necrosis factor-mediated signaling pathway 167 1.998 1.97E-06 1.08E-04 0.463
GO:0038094 Fc-gamma receptor signaling pathway 142 2.607 1.97E-06 1.08E-04 0.642
GO:0002526 acute inflammatory response 220 2.600 1.97E-06 1.08E-04 0.558
GO:1901136 carbohydrate derivative catabolic process 192 2.362 1.97E-06 1.08E-04 0.421
GO:0061025 membrane fusion 154 2.299 1.97E-06 1.08E-04 0.505
GO:0043281
regulation of cysteine-type endopeptidase activity involved in 
apoptotic process 215 1.926 1.97E-06 1.08E-04 0.400
GO:0000070 mitotic sister chromatid segregation 151 2.028 1.97E-06 1.08E-04 0.273
GO:0038061 NIK/NF-kappaB signaling 183 1.940 1.97E-06 1.08E-04 0.489
GO:0050864 regulation of B cell activation 184 1.949 1.97E-06 1.08E-04 0.500
GO:0007033 vacuole organization 163 2.177 1.97E-06 1.08E-04 0.459
GO:0044106 cellular amine metabolic process 129 2.214 1.97E-06 1.08E-04 0.571
GO:0055067 monovalent inorganic cation homeostasis 154 2.237 1.97E-06 1.08E-04 0.528
GO:1902750 negative regulation of cell cycle G2/M phase transition 105 2.142 1.97E-06 1.08E-04 0.455
GO:0002474
antigen processing and presentation of peptide antigen via MHC 
class I 96 2.509 1.97E-06 1.08E-04 0.505
GO:0070498 interleukin-1-mediated signaling pathway 100 2.216 1.97E-06 1.08E-04 0.553
GO:0031145 anaphase-promoting complex-dependent catabolic process 81 2.425 1.97E-06 1.08E-04 0.494
GO:0009060 aerobic respiration 87 2.366 1.97E-06 1.08E-04 0.493
GO:0032612 interleukin-1 production 115 2.113 1.97E-06 1.08E-04 0.557
GO:0043648 dicarboxylic acid metabolic process 99 2.163 1.97E-06 1.08E-04 0.545
GO:0061418
regulation of transcription from RNA polymerase II promoter in 
response to hypoxia 77 2.189 1.97E-06 1.08E-04 0.559
GO:0045454 cell redox homeostasis 76 2.361 1.97E-06 1.08E-04 0.607
GO:0045851 pH reduction 53 2.280 1.97E-06 1.08E-04 0.625
GO:1901658 glycosyl compound catabolic process 43 2.264 1.98E-06 1.08E-04 0.457
GO:0006614 SRP-dependent cotranslational protein targeting to membrane 105 -2.113 2.03E-06 1.09E-04 0.611
GO:0140014 mitotic nuclear division 264 1.766 3.93E-06 1.76E-04 0.227
GO:0005996 monosaccharide metabolic process 292 1.833 3.93E-06 1.76E-04 0.384
GO:0010466 negative regulation of peptidase activity 262 1.999 3.94E-06 1.76E-04 0.485
GO:0008037 cell recognition 215 2.040 3.94E-06 1.76E-04 0.535
GO:0016999 antibiotic metabolic process 151 2.091 3.94E-06 1.76E-04 0.480
GO:0019682 glyceraldehyde-3-phosphate metabolic process 21 2.271 3.95E-06 1.76E-04 0.643
GO:0006739 NADP metabolic process 32 2.271 3.95E-06 1.76E-04 0.542
GO:0007040 lysosome organization 61 2.170 3.95E-06 1.76E-04 0.611
GO:0031668 cellular response to extracellular stimulus 268 1.787 5.90E-06 2.50E-04 0.457
GO:0009152 purine ribonucleotide biosynthetic process 280 1.768 5.90E-06 2.50E-04 0.303
GO:0042180 cellular ketone metabolic process 248 1.838 5.90E-06 2.50E-04 0.481
GO:0006376 mRNA splice site selection 53 -2.321 6.08E-06 2.54E-04 0.323
GO:0044839 cell cycle G2/M phase transition 266 1.740 7.85E-06 3.08E-04 0.379
GO:0097164 ammonium ion metabolic process 205 1.884 7.87E-06 3.08E-04 0.472
GO:0016051 carbohydrate biosynthetic process 214 1.864 7.87E-06 3.08E-04 0.444
GO:0006900 vesicle budding from membrane 102 1.990 7.88E-06 3.08E-04 0.452
GO:0000395 mRNA 5'-splice site recognition 29 -2.217 8.11E-06 3.13E-04 0.583
GO:1901988 negative regulation of cell cycle phase transition 267 1.757 9.82E-06 3.65E-04 0.432
GO:0050701 interleukin-1 secretion 61 2.137 9.87E-06 3.65E-04 0.556
GO:0034341 response to interferon-gamma 199 1.834 1.18E-05 4.15E-04 0.410
GO:0007032 endosome organization 79 2.034 1.18E-05 4.15E-04 0.528
GO:0006140 regulation of nucleotide metabolic process 146 1.924 1.38E-05 4.61E-04 0.368
GO:0044242 cellular lipid catabolic process 217 1.835 1.38E-05 4.61E-04 0.456
GO:0072350 tricarboxylic acid metabolic process 39 2.150 1.38E-05 4.61E-04 0.606
GO:0032635 interleukin-6 production 161 1.859 1.57E-05 4.99E-04 0.505
GO:1902850 microtubule cytoskeleton organization involved in mitosis 131 1.891 1.57E-05 4.99E-04 0.330
GO:0033572 transferrin transport 36 2.163 1.58E-05 4.99E-04 0.643
GO:0002532 production of molecular mediator involved in inflammatory response 72 2.091 1.58E-05 4.99E-04 0.608
GO:0034381 plasma lipoprotein particle clearance 69 2.122 1.78E-05 5.44E-04 0.629
GO:0048771 tissue remodeling 179 1.894 1.97E-05 5.85E-04 0.505
GO:0051304 chromosome separation 90 1.965 1.97E-05 5.85E-04 0.267
GO:0018196 peptidyl-asparagine modification 34 2.160 1.97E-05 5.85E-04 0.484
GO:0009595 detection of biotic stimulus 23 2.171 1.98E-05 5.85E-04 0.800
GO:0046466 membrane lipid catabolic process 35 2.157 2.76E-05 7.49E-04 0.692
GO:0071216 cellular response to biotic stimulus 236 1.756 3.15E-05 8.42E-04 0.421
GO:0050663 cytokine secretion 240 1.742 3.35E-05 8.87E-04 0.425
GO:0042116 macrophage activation 95 1.970 3.95E-05 1.01E-03 0.529
GO:0007584 response to nutrient 219 1.765 4.33E-05 1.09E-03 0.517
GO:0000041 transition metal ion transport 112 1.924 4.34E-05 1.09E-03 0.467
GO:0051262 protein tetramerization 172 1.812 4.53E-05 1.12E-03 0.311
GO:0006364 rRNA processing 214 -1.717 4.69E-05 1.13E-03 0.420
GO:0060337 type I interferon signaling pathway 95 1.933 4.93E-05 1.16E-03 0.500
GO:0006643 membrane lipid metabolic process 207 1.749 5.32E-05 1.24E-03 0.403
GO:0019083 viral transcription 177 -1.732 5.69E-05 1.32E-03 0.465
GO:0042737 drug catabolic process 140 1.906 5.92E-05 1.37E-03 0.427
GO:0000184
nuclear-trans ribed mRNA catabolic process, nonsense-mediated 
decay 120 -1.808 6.51E-05 1.48E-03 0.576
GO:0006081 cellular aldehyde metabolic process 74 2.030 6.52E-05 1.48E-03 0.568
GO:0010499 proteasomal ubiquitin-independent protein catabolic process 23 2.118 6.70E-05 1.52E-03 0.524
GO:0051701 interaction with host 209 1.707 7.47E-05 1.64E-03 0.416
GO:0002220
i nate immune response activating cell surface receptor signaling 
pathway 116 1.835 8.07E-05 1.74E-03 0.580
GO:0051225 spindle assembly 108 1.833 8.87E-05 1.87E-03 0.284
GO:0050764 regulation of phagocytosis 98 1.880 8.88E-05 1.87E-03 0.547
GO:0032418 lysosome localization 74 1.947 9.28E-05 1.93E-03 0.632
GO:0070646 protein modification by small protein removal 299 1.607 1.04E-04 2.16E-03 0.440
GO:0006479 protein methylation 179 -1.744 1.12E-04 2.28E-03 0.421
GO:0016197 endosomal transport 224 1.670 1.12E-04 2.28E-03 0.415
GO:0090288 negative regulation of cellular response to growth factor stimulus 166 -1.858 1.18E-04 2.38E-03 0.415
GO:0043112 receptor metabolic process 192 1.733 1.24E-04 2.49E-03 0.455
GO:0032868 response to insulin 272 1.641 1.51E-04 2.93E-03 0.402
GO:1905330 regulation of morphogenesis of an epithelium 180 1.752 1.77E-04 3.35E-03 0.496
GO:0046365 monosaccharide catabolic process 67 1.941 1.80E-04 3.39E-03 0.408
GO:0097205 renal filtration 22 2.059 1.83E-04 3.45E-03 0.615
GO:0090175 regulation of establishment of planar polarity 110 1.799 2.21E-04 4.05E-03 0.512
GO:0032722 positive regulation of chemokine production 58 1.937 2.45E-04 4.42E-03 0.561
GO:1902600 proton transmembrane transport 163 1.771 2.52E-04 4.52E-03 0.547
GO:0030193 regulation of blood coagulation 79 1.915 2.62E-04 4.67E-03 0.511
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER 86 1.818 2.66E-04 4.72E-03 0.455
GO:0002573 myeloid leukocyte differentiation 204 1.656 2.85E-04 4.97E-03 0.497
GO:0002793 positive regulation of peptide secretion 288 1.608 2.97E-04 5.13E-03 0.361
GO:0060759 regulation of response to cytokine stimulus 190 1.678 3.05E-04 5.25E-03 0.430
GO:1901568 fatty acid derivative metabolic process 167 1.764 3.11E-04 5.32E-03 0.355
GO:0042133 neurotransmitter metabolic process 153 1.777 3.11E-04 5.32E-03 0.494
GO:0031638 zymogen activation 53 1.988 3.12E-04 5.32E-03 0.567
GO:0036109 alpha-linolenic acid metabolic process 13 2.011 3.40E-04 5.74E-03 0.727
GO:0034976 response to endoplasmic reticulum stress 285 1.564 3.59E-04 5.95E-03 0.416
GO:0031639 plasminogen activation 25 2.011 3.73E-04 6.09E-03 0.538
GO:0046364 monosaccharide biosynthetic process 98 1.813 3.77E-04 6.14E-03 0.443
GO:1902476 chloride transmembrane transport 88 1.956 3.93E-04 6.31E-03 0.424
GO:0032637 interleukin-8 production 82 1.841 3.97E-04 6.35E-03 0.533
GO:0009566 fertilization 182 1.803 4.20E-04 6.69E-03 0.451
GO:1902036 regulation of hematopoietic stem cell differentiation 72 1.812 4.73E-04 7.48E-03 0.379
GO:0006801 superoxide metabolic process 73 1.860 4.92E-04 7.66E-03 0.588
GO:0006575 cellular modified amino acid metabolic process 202 1.666 4.92E-04 7.66E-03 0.484
GO:0043174 nucleoside salvage 16 1.991 4.93E-04 7.66E-03 0.462
GO:0006027 glycosaminoglycan catabolic process 61 1.949 5.19E-04 7.99E-03 0.586
GO:1903008 organelle disassembly 101 1.730 5.54E-04 8.49E-03 0.467
GO:0090092
re ulation of transmembrane receptor protein serine/threonine kinase 
signaling pathway 241 -1.668 5.73E-04 8.77E-03 0.366
GO:0008217 regulation of blood pressure 182 1.756 5.80E-04 8.84E-03 0.325
GO:0006888 ER to Golgi vesicle-mediated transport 212 1.585 5.96E-04 9.05E-03 0.420
GO:0043154
negative regulation of cyst ine-type endopeptidase activity involved 
in apoptotic process 84 1.802 6.10E-04 9.20E-03 0.500
GO:2000379 positive regulation of reactive oxygen species metabolic process 102 1.768 6.32E-04 9.50E-03 0.542
GO:0045730 respiratory burst 37 1.930 6.46E-04 9.65E-03 0.552
GO:0007029 endoplasmic reticulum organization 57 1.873 6.47E-04 9.65E-03 0.575
GO:0071772 response to BMP 170 -1.754 6.67E-04 9.80E-03 0.403
GO:0002755 MyD88-dependent toll-like receptor signaling pathway 36 1.901 6.84E-04 9.94E-03 0.471
GO:1903557
positive regulation of tumor necrosi  factor superfamily cytokine 
production 88 1.760 7.18E-04 1.03E-02 0.486
GO:0006672 ceramide metabolic process 92 1.780 7.34E-04 1.04E-02 0.530
GO:1903034 regulation of response to wounding 179 1.671 7.51E-04 1.06E-02 0.448
GO:0007034 vacuolar transport 142 1.629 7.74E-04 1.08E-02 0.414
GO:0090263 positive regulation of canonical Wnt signaling pathway 147 1.666 7.79E-04 1.08E-02 0.327
GO:1901216 positive regulation of neuron death 94 1.742 7.81E-04 1.08E-02 0.533
GO:0048260 positive regulation of receptor-mediated endocytosis 51 1.895 7.82E-04 1.08E-02 0.576
GO:0033865 nucleoside bisphosphate metabolic process 140 1.670 8.09E-04 1.11E-02 0.346
GO:1901605 alpha-amino acid metabolic process 222 1.612 8.46E-04 1.15E-02 0.449
GO:0010821 regulation of mitochondrion organization 182 1.587 8.53E-04 1.16E-02 0.290
GO:0016125 sterol metabolic process 166 1.657 8.81E-04 1.19E-02 0.352
GO:2001234 negative regulation of apoptotic signaling pathway 230 1.568 8.97E-04 1.21E-02 0.395
GO:0098754 detoxification 131 1.717 9.41E-04 1.25E-02 0.506
GO:0006919
activation of cysteine-type endopeptidase activity involved in 
apoptotic process 86 1.753 9.63E-04 1.27E-02 0.426
GO:0046470 phosphatidylcholine metabolic process 83 1.804 9.73E-04 1.28E-02 0.481
GO:0051321 meiotic cell cycle 249 1.596 9.94E-04 1.30E-02 0.275
GO:0097352 autophagosome maturation 38 1.873 1.02E-03 1.33E-02 0.424
GO:0001510 RNA methylation 81 -1.737 1.17E-03 1.48E-02 0.279
GO:0032799 low-density lipoprotein receptor particle metabolic process 23 1.916 1.21E-03 1.52E-02 0.684
GO:0045471 response to ethanol 125 1.733 1.22E-03 1.53E-02 0.471
GO:0031060 regulation of histone methylation 65 -1.774 1.23E-03 1.53E-02 0.509
GO:1903531 negative regulation of secretion by cell 211 1.615 1.28E-03 1.57E-02 0.410
GO:0019321 pentose metabolic process 15 1.912 1.30E-03 1.59E-02 0.500
GO:0048259 regulation of receptor-mediated endocytosis 103 1.743 1.30E-03 1.60E-02 0.452
GO:0061647 histone H3-K9 modification 48 -1.819 1.38E-03 1.67E-02 0.564
GO:0072329 monocarboxylic acid catabolic process 132 1.650 1.47E-03 1.77E-02 0.411
GO:0017001 antibiotic catabolic process 58 1.825 1.48E-03 1.78E-02 0.500
GO:0030041 actin filament polymerization 182 1.576 1.56E-03 1.86E-02 0.493
GO:0042053 regulation of dopamine metabolic process 20 1.901 1.56E-03 1.86E-02 0.818
GO:0042058 regulation of epidermal growth factor receptor signaling pathway 86 1.714 1.59E-03 1.88E-02 0.576
GO:0140029 exocytic process 80 1.732 1.70E-03 1.98E-02 0.526
GO:0051984 positive regulation of chromosome segregation 28 1.864 1.75E-03 2.02E-02 0.240
GO:0061640 cytoskeleton-dependent cytokinesis 100 1.688 1.76E-03 2.03E-02 0.417
GO:0006123 mitochondrial electron transport, cytochrome c to oxygen 21 1.890 1.77E-03 2.03E-02 0.706
GO:1904668 positive regulation of ubiquitin protein ligase activity 12 1.889 1.79E-03 2.05E-02 0.545
GO:0042471 ear morphogenesis 118 -1.775 1.84E-03 2.10E-02 0.409
GO:0031146
SCF-de end t proteasomal ubiquitin-dependent protein catabolic 
process 95 1.658 1.86E-03 2.12E-02 0.373
GO:0033077 T cell differentiation in thymus 70 -1.737 1.87E-03 2.12E-02 0.455
GO:1903509 liposaccharide metabolic process 111 1.654 1.89E-03 2.14E-02 0.405
GO:0002576 platelet degranulation 128 1.636 1.90E-03 2.15E-02 0.516
GO:0050862 positive regulation of T cell receptor signaling pathway 14 -1.897 2.02E-03 2.25E-02 0.750
GO:0050820 positive regulation of coagulation 27 1.872 2.07E-03 2.31E-02 0.579
GO:0043277 apoptotic cell clearance 46 1.813 2.12E-03 2.34E-02 0.750
GO:0022618 ribonucleoprotein complex assembly 277 -1.471 2.14E-03 2.36E-02 0.294
GO:0045410 positive regulation of interleukin-6 biosynthetic process 15 1.878 2.17E-03 2.39E-02 0.733
GO:0036258 multivesicular body assembly 30 1.828 2.19E-03 2.40E-02 0.607
GO:0010823 negative regulation of mitochondrion organization 55 1.758 2.20E-03 2.41E-02 0.409
GO:0036124 histone H3-K9 trimethylation 16 -1.887 2.23E-03 2.43E-02 0.615
GO:0006907 pinocytosis 21 1.874 2.25E-03 2.44E-02 0.563
GO:0090148 membrane fission 12 1.869 2.26E-03 2.45E-02 0.700
GO:0007229 integrin-mediated signaling pathway 103 1.659 2.34E-03 2.52E-02 0.459
GO:0010257 NADH dehydrogenase complex assembly 64 1.698 2.35E-03 2.52E-02 0.383
GO:1900407 regulation of cellular response to oxidative stress 88 1.700 2.38E-03 2.54E-02 0.441
GO:0032506 cytokinetic process 39 1.779 2.42E-03 2.58E-02 0.459
GO:0001845 phagolysosome assembly 13 1.863 2.43E-03 2.58E-02 0.600
GO:1904385 cellular response to angiotensin 25 1.867 2.45E-03 2.59E-02 0.400
GO:0045132 meiotic chromosome segregation 90 1.738 2.48E-03 2.60E-02 0.234
GO:0060395 SMAD protein signal transduction 70 -1.787 2.51E-03 2.63E-02 0.412
GO:0021700 developmental maturation 284 1.515 2.56E-03 2.66E-02 0.442
GO:0015718 monocarboxylic acid transport 162 1.632 2.64E-03 2.72E-02 0.537
GO:0090596 sensory organ morphogenesis 256 -1.590 2.65E-03 2.72E-02 0.419
GO:0043094 cellular metabolic compound salvage 34 1.821 2.65E-03 2.72E-02 0.385
GO:0072523 purine-containing compound catabolic process 51 1.772 2.66E-03 2.73E-02 0.278
GO:0089718 amino acid import across plasma membrane 23 1.860 2.68E-03 2.74E-02 0.750
GO:0033194 response to hydroperoxide 20 1.854 2.68E-03 2.74E-02 0.647
GO:0017157 regulation of exocytosis 217 1.548 2.73E-03 2.77E-02 0.394
GO:0030510 regulation of BMP signaling pathway 91 -1.744 2.76E-03 2.79E-02 0.381
GO:0043627 response to estrogen 73 1.734 2.87E-03 2.89E-02 0.477
GO:0003071
r nal system process involved in regulation of systemic arterial blood 
pressure 25 1.849 2.87E-03 2.89E-02 0.600
GO:1903076 regulation of protein localization to plasma membrane 95 1.664 2.96E-03 2.96E-02 0.477
GO:0097066 response to thyroid hormone 26 1.841 2.99E-03 2.98E-02 0.556
GO:0043300 regulation of leukocyte degranulation 46 1.742 3.06E-03 3.04E-02 0.550
GO:2000482 regulation of interleukin-8 secretion 25 1.828 3.06E-03 3.04E-02 0.700
GO:0002082 regulation of oxidative phosphorylation 31 1.824 3.08E-03 3.05E-02 0.455
GO:0043624 cellular protein complex disassembly 217 1.483 3.10E-03 3.07E-02 0.447
GO:0098656 anion transmembrane transport 288 1.497 3.20E-03 3.16E-02 0.469
GO:0019674 NAD metabolic process 76 1.687 3.25E-03 3.20E-02 0.519
GO:0046835 carbohydrate phosphorylation 24 1.832 3.26E-03 3.20E-02 0.556
GO:2001057 reactive nitrogen species metabolic process 85 1.681 3.30E-03 3.23E-02 0.509
GO:0046683 response to organophosphorus 134 1.611 3.36E-03 3.28E-02 0.354
GO:0009451 RNA modification 163 -1.523 3.39E-03 3.29E-02 0.264
GO:0070125 mitochondrial translational elongation 88 1.613 3.43E-03 3.33E-02 0.481
GO:0051650 establishment of vesicle localization 290 1.454 3.54E-03 3.42E-02 0.429
GO:0031348 negative regulation of defense response 239 1.504 3.61E-03 3.47E-02 0.388
GO:0018023 peptidyl-lysine trimethylation 44 -1.751 3.61E-03 3.47E-02 0.500
GO:0006767 water-soluble vitamin metabolic process 88 1.633 3.68E-03 3.53E-02 0.449
GO:0006836 neurotransmitter transport 269 1.524 3.69E-03 3.53E-02 0.426
GO:0010507 negative regulation of autophagy 84 1.640 3.87E-03 3.67E-02 0.438
GO:0051307 meiotic chromosome separation 25 1.825 3.92E-03 3.71E-02 0.357
GO:0060986 endocrine hormone secretion 47 -1.818 3.96E-03 3.73E-02 0.333
GO:0032928 regulation of superoxide anion generation 22 1.814 4.04E-03 3.79E-02 0.824
GO:0034446 substrate adhesion-dependent cell spreading 100 1.639 4.05E-03 3.79E-02 0.508
GO:0060042 retina morphogenesis in camera-type eye 49 -1.819 4.13E-03 3.84E-02 0.412
GO:0072665 protein localization to vacuole 65 1.657 4.21E-03 3.91E-02 0.536
GO:0008347 glial cell migration 49 1.738 4.39E-03 4.04E-02 0.455
GO:0051931 regulation of sensory perception 40 1.815 4.39E-03 4.04E-02 0.583
GO:0097028 dendritic cell differentiation 42 1.741 4.47E-03 4.08E-02 0.531
GO:0006607 NLS-bearing protein import into nucleus 18 -1.804 4.54E-03 4.14E-02 0.389
GO:0016573 histone acetylation 156 -1.507 4.58E-03 4.17E-02 0.386
GO:0060021 roof of mouth development 89 -1.674 4.59E-03 4.17E-02 0.313
GO:0006730 one-carbon metabolic process 27 1.778 4.63E-03 4.20E-02 0.609
GO:0051187 cofactor catabolic process 65 1.726 4.66E-03 4.21E-02 0.324
GO:0051785 positive regulation of nuclear division 66 1.696 4.72E-03 4.27E-02 0.317
GO:0043032 positive regulation of macrophage activation 27 1.803 4.75E-03 4.28E-02 0.533
GO:0034142 toll-like receptor 4 signaling pathway 35 1.765 4.77E-03 4.28E-02 0.720
GO:0006691 leukotriene metabolic process 31 1.805 4.79E-03 4.30E-02 0.429
GO:0044275 cellular carbohydrate catabolic process 45 1.722 4.84E-03 4.32E-02 0.441
GO:0030316 osteoclast differentiation 97 1.599 4.86E-03 4.33E-02 0.542
GO:0008637 apoptotic mitochondrial changes 124 1.548 4.90E-03 4.35E-02 0.367
GO:0051881 regulation of mitochondrial membrane potential 72 1.651 4.91E-03 4.35E-02 0.434
GO:0051965 positive regulation of synapse assembly 68 -1.788 4.93E-03 4.36E-02 0.650
GO:0051988 regulation of attachment of spindle microtubules to kinetochore 12 1.803 5.05E-03 4.44E-02 0.750
GO:0031056 regulation of histone modification 143 -1.518 5.06E-03 4.44E-02 0.387
GO:0043902 positive regulation of multi-organism process 188 1.475 5.16E-03 4.53E-02 0.376
GO:0050729 positive regulation of inflammatory response 153 1.549 5.19E-03 4.53E-02 0.389
GO:0097191 extrinsic apoptotic signaling pathway 224 1.456 5.25E-03 4.58E-02 0.405
GO:0001774 microglial cell activation 48 1.705 5.30E-03 4.60E-02 0.417
GO:0034058 endosomal vesicle fusion 10 1.791 5.36E-03 4.63E-02 0.700
GO:0035635 entry of bacterium into host cell 15 1.791 5.36E-03 4.63E-02 0.600
GO:0002385 mucosal immune response 36 -1.784 5.43E-03 4.68E-02 0.444
GO:0006022 aminoglycan metabolic process 170 1.539 5.51E-03 4.71E-02 0.402
GO:2000756 regulation of peptidyl-lysine acetylation 59 -1.657 5.67E-03 4.84E-02 0.383
GO:1905819 negative regulation of chromosome separation 40 1.704 5.76E-03 4.89E-02 0.324
GO:0019432 triglyceride biosynthetic process 41 1.747 5.84E-03 4.91E-02 0.500
GO:0001659 temperature homeostasis 173 1.508 5.93E-03 4.96E-02 0.316
Legend
Size Number of genes defining the biological process in the GO database 
NES
ormalize Enrichment Score, indicating the l vel of enrichment and 
its directionality
pvalue
Empirical st tistical significance value for enrichment (n=1e6 
permutations)
p.adjust FDR-corrected p-value
ratio*
Ratio betwe n #core BP enriched genes and #total genes in 
biological process
*As described in https://www.gsea-
msigdb.org/gsea/doc/GSEAUserGuideFrame.html
Supplementary Table 2: List of biological processes associated to treatment with abatacept
ID Description Size NES pvalue p.adjust ratio
GO:0140014 mitotic nuclear division 264 -2.222 1.75E-06 1.28E-04 0.394
GO:0038093 Fc receptor signaling pathway 241 -3.021 1.76E-06 1.28E-04 0.371
GO:1901988 negative regulation of cell cycle phase transition 267 -1.811 1.76E-06 1.28E-04 0.295
GO:0002440 production of molecular mediator of immune response 286 -2.758 1.76E-06 1.28E-04 0.216
GO:0045637 regulation of myeloid cell differentiation 251 -1.959 1.76E-06 1.28E-04 0.388
GO:0019882 antigen processing and presentation 226 -1.972 1.77E-06 1.28E-04 0.369
GO:0050864 regulation of B cell activation 184 -2.765 1.81E-06 1.28E-04 0.326
GO:0002526 acute inflammatory response 220 -3.092 1.81E-06 1.28E-04 0.379
GO:0031497 chromatin assembly 165 -2.643 1.81E-06 1.28E-04 0.401
GO:0000070 mitotic sister chromatid segregation 151 -2.243 1.81E-06 1.28E-04 0.382
GO:2001251 negative regulation of chromosome organization 146 -2.297 1.82E-06 1.28E-04 0.380
GO:0038094 Fc-gamma receptor signaling pathway 142 -3.182 1.82E-06 1.28E-04 0.531
GO:0008037 cell recognition 215 -2.611 1.82E-06 1.28E-04 0.328
GO:0045814 negative regulation of gene expression, epigenetic 136 -2.335 1.83E-06 1.28E-04 0.441
GO:1902850 microtubule cytoskeleton organization involved in mitosis 131 -2.213 1.83E-06 1.28E-04 0.461
GO:0002455 humoral immune response mediated by circulating immunoglobulin 150 -3.253 1.85E-06 1.28E-04 0.612
GO:0010324 membrane invagination 135 -2.837 1.85E-06 1.28E-04 0.418
GO:0051225 spindle assembly 108 -2.041 1.85E-06 1.28E-04 0.443
GO:0045652 regulation of megakaryocyte differentiation 79 -2.168 1.87E-06 1.28E-04 0.432
GO:0051304 chromosome separation 90 -2.215 1.87E-06 1.28E-04 0.297
GO:0006335 DNA replication-dependent nucleosome assembly 32 -2.217 1.94E-06 1.28E-04 0.531
GO:0019731 antibacterial humoral response 46 -2.234 1.95E-06 1.28E-04 0.655
GO:0042274 ribosomal small subunit biogenesis 67 2.163 2.13E-06 1.28E-04 0.569
GO:0042273 ribosomal large subunit biogenesis 71 2.214 2.14E-06 1.28E-04 0.500
GO:0002181 cytoplasmic translation 100 2.017 2.18E-06 1.28E-04 0.404
GO:0006614 SRP-dependent cotranslational protein targeting to membrane 105 2.746 2.18E-06 1.28E-04 0.704
GO:0000184 nuclear-transcribed mRNA catabolic process, nonsense-mediated decay 120 2.663 2.21E-06 1.28E-04 0.563
GO:0019083 viral transcription 177 2.439 2.27E-06 1.28E-04 0.494
GO:0006413 translational initiation 193 2.229 2.28E-06 1.28E-04 0.421
GO:0006364 rRNA processing 214 2.183 2.31E-06 1.28E-04 0.419
GO:0051290 protein heterotetramerization 54 -2.125 3.82E-06 1.92E-04 0.396
GO:1905819 negative regulation of chromosome separation 40 -2.197 3.87E-06 1.92E-04 0.382
GO:0007093 mitotic cell cycle checkpoint 165 -1.849 5.41E-06 2.58E-04 0.300
GO:0060147 regulation of posttranscriptional gene silencing 117 -2.000 5.51E-06 2.58E-04 0.306
GO:0009451 RNA modification 163 1.829 6.75E-06 2.97E-04 0.294
GO:0038111 interleukin-7-mediated signaling pathway 30 -2.135 7.81E-06 3.37E-04 0.571
GO:0000028 ribosomal small subunit assembly 19 2.131 8.03E-06 3.44E-04 0.706
GO:0019730 antimicrobial humoral response 122 -2.052 1.13E-05 4.74E-04 0.450
GO:0090224 regulation of spindle organization 41 -2.110 1.35E-05 5.51E-04 0.568
GO:0030261 chromosome condensation 47 -2.099 1.35E-05 5.51E-04 0.667
GO:0000027 ribosomal large subunit assembly 30 2.124 1.64E-05 6.33E-04 0.679
GO:0001510 RNA methylation 81 1.953 2.15E-05 8.25E-04 0.359
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER 86 -1.947 2.99E-05 1.13E-03 0.418
GO:0008033 tRNA processing 130 1.803 3.11E-05 1.16E-03 0.250
GO:0006338 chromatin remodeling 182 -1.771 3.23E-05 1.19E-03 0.369
GO:0090068 positive regulation of cell cycle process 298 -1.670 3.33E-05 1.22E-03 0.295
GO:0051310 metaphase plate congression 57 -2.011 3.43E-05 1.25E-03 0.431
GO:1901216 positive regulation of neuron death 94 -1.930 4.30E-05 1.54E-03 0.382
GO:0070125 mitochondrial translational elongation 88 1.892 4.55E-05 1.60E-03 0.322
GO:0051321 meiotic cell cycle 249 -1.721 1.06E-04 3.60E-03 0.188
GO:0044839 cell cycle G2/M phase transition 266 -1.618 1.15E-04 3.86E-03 0.238
GO:0022618 ribonucleoprotein complex assembly 277 1.576 1.54E-04 5.06E-03 0.399
GO:0016236 macroautophagy 295 -1.572 1.56E-04 5.07E-03 0.365
GO:0032886 regulation of microtubule-based process 218 -1.659 1.59E-04 5.07E-03 0.270
GO:0050830 defense response to Gram-positive bacterium 101 -1.909 1.59E-04 5.07E-03 0.400
GO:0034976 response to endoplasmic reticulum stress 285 -1.592 1.64E-04 5.17E-03 0.243
GO:0045132 meiotic chromosome segregation 90 -1.902 2.15E-04 6.60E-03 0.235
GO:0000082 G1/S transition of mitotic cell cycle 279 -1.597 2.20E-04 6.69E-03 0.256
GO:0060969 negative regulation of gene silencing 39 -1.957 2.32E-04 7.02E-03 0.433
GO:0051262 protein tetramerization 172 -1.699 2.50E-04 7.51E-03 0.248
GO:0002474 antigen processing and presentation of peptide antigen via MHC class I 96 -1.780 2.52E-04 7.53E-03 0.333
GO:0032635 interleukin-6 production 161 -1.728 2.62E-04 7.78E-03 0.427
GO:1905268 negative regulation of chromatin organization 62 -1.878 2.90E-04 8.46E-03 0.412
GO:0036498 IRE1-mediated unfolded protein response 64 -1.856 3.02E-04 8.77E-03 0.483
GO:0031167 rRNA methylation 27 1.942 3.04E-04 8.77E-03 0.440
GO:0043388 positive regulation of DNA binding 59 -1.897 3.14E-04 9.03E-03 0.455
GO:0000470 maturation of LSU-rRNA 21 1.916 4.73E-04 1.33E-02 0.571
GO:0061640 cytoskeleton-dependent cytokinesis 100 -1.763 4.92E-04 1.37E-02 0.314
GO:0000727 double-strand break repair via break-induced replication 11 -1.888 5.04E-04 1.40E-02 0.500
GO:0008608 attachment of spindle microtubules to kinetochore 32 -1.904 5.29E-04 1.45E-02 0.429
GO:0032715 negative regulation of interleukin-6 production 53 -1.874 5.31E-04 1.45E-02 0.425
GO:0051701 interaction with host 209 -1.602 5.64E-04 1.52E-02 0.297
GO:0032868 response to insulin 272 -1.559 6.21E-04 1.65E-02 0.335
GO:0016052 carbohydrate catabolic process 199 -1.605 6.91E-04 1.83E-02 0.304
GO:0007062 sister chromatid cohesion 63 -1.807 7.24E-04 1.91E-02 0.232
GO:1902969 mitotic DNA replication 15 -1.894 7.48E-04 1.96E-02 0.571
GO:0007033 vacuole organization 163 -1.619 7.52E-04 1.96E-02 0.355
GO:0050764 regulation of phagocytosis 98 -1.748 8.13E-04 2.09E-02 0.468
GO:0002701 negative regulation of production of molecular mediator of immune response 35 -1.884 8.17E-04 2.09E-02 0.269
GO:0042770 signal transduction in response to DNA damage 133 -1.662 8.28E-04 2.10E-02 0.294
GO:0030100 regulation of endocytosis 281 -1.544 8.78E-04 2.21E-02 0.393
GO:0000018 regulation of DNA recombination 101 -1.719 8.80E-04 2.21E-02 0.333
GO:0033260 nuclear DNA replication 60 -1.770 1.11E-03 2.70E-02 0.345
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading 37 -1.846 1.22E-03 2.97E-02 0.552
GO:2001235 positive regulation of apoptotic signaling pathway 179 -1.588 1.25E-03 3.03E-02 0.291
GO:0032465 regulation of cytokinesis 89 -1.726 1.40E-03 3.33E-02 0.279
GO:1902115 regulation of organelle assembly 194 -1.566 1.41E-03 3.34E-02 0.400
GO:0031935 regulation of chromatin silencing 37 -1.831 1.44E-03 3.38E-02 0.367
GO:0031099 regeneration 198 -1.622 1.49E-03 3.47E-02 0.413
GO:0045730 respiratory burst 37 -1.824 1.51E-03 3.50E-02 0.469
GO:0051099 positive regulation of binding 179 -1.583 1.53E-03 3.53E-02 0.276
GO:0018107 peptidyl-threonine phosphorylation 126 -1.639 1.57E-03 3.60E-02 0.264
GO:1904668 positive regulation of ubiquitin protein ligase activity 12 -1.835 1.57E-03 3.60E-02 0.273
GO:0051965 positive regulation of synapse assembly 68 1.794 1.62E-03 3.69E-02 0.364
GO:0016482 cytosolic transport 158 -1.576 1.67E-03 3.78E-02 0.324
GO:0002385 mucosal immune response 36 -1.837 1.71E-03 3.85E-02 0.542
GO:0071216 cellular response to biotic stimulus 236 -1.529 1.72E-03 3.86E-02 0.385
GO:0044003 modification by symbiont of host morphology or physiology 46 -1.786 1.81E-03 3.99E-02 0.359
GO:0051984 positive regulation of chromosome segregation 28 -1.825 1.85E-03 4.01E-02 0.346
GO:0043044 ATP-dependent chromatin remodeling 88 -1.685 1.86E-03 4.01E-02 0.368
GO:0000083 regulation of transcription involved in G1/S transition of mitotic cell cycle 29 -1.827 1.88E-03 4.05E-02 0.280
GO:0051053 negative regulation of DNA metabolic process 156 -1.588 1.94E-03 4.16E-02 0.277
GO:0031330 negative regulation of cellular catabolic process 264 -1.495 2.09E-03 4.39E-02 0.336
GO:0048771 tissue remodeling 179 -1.613 2.11E-03 4.39E-02 0.367
GO:0002573 myeloid leukocyte differentiation 204 -1.541 2.16E-03 4.46E-02 0.344
GO:0003014 renal system process 120 -1.691 2.17E-03 4.46E-02 0.232
GO:0030262 apoptotic nuclear changes 35 -1.802 2.21E-03 4.50E-02 0.483
GO:0046653 tetrahydrofolate metabolic process 19 -1.829 2.23E-03 4.53E-02 0.438
GO:0050777 negative regulation of immune response 150 -1.596 2.41E-03 4.81E-02 0.248
Legend
Size Number of genes defining the biological process in the GO database 
NES Normalize Enrichment Score, indicating the level of enrichment and its directionality
pvalue Empirical statistical significance value for enrichment (n=1e6 permutations)
p.adjust FDR-corrected p-value
ratio* Ratio between #core BP enriched genes and #total genes in biological process
*As described in https://www.gsea-msigdb.org/gsea/doc/GSEAUserGuideFrame.html
Supplementary Table 3: List of overlapping biologial processes between COVID19 and abatacept exposures
ID Description Size NES_COVID pCOVID ratio_COVID NES_ABT pABT ratio_ABT
GO:0000070 mitotic sister chromatid segregation 151 2.028 1.08E-04 0.273 -2.243 1.28E-04 0.382
GO:0000184
nuclear-transcribed mRNA catabolic process, nonsense-
mediated decay 120 -1.808 1.48E-03 0.576 2.663 1.28E-04 0.563
GO:0001510 RNA methylation 81 -1.737 1.48E-02 0.279 1.953 8.25E-04 0.359
GO:0002385 mucosal immune response 36 -1.784 4.68E-02 0.444 -1.837 3.85E-02 0.542
GO:0002440 production of molecular mediator of immune response 286 1.918 1.08E-04 0.442 -2.758 1.28E-04 0.216
GO:0002455
humoral immune response mediated by circulating 
immunoglobulin 150 3.043 1.08E-04 0.739 -3.253 1.28E-04 0.612
GO:0002474
antigen processing and presentation of peptide antigen 
via MHC class I 96 2.509 1.08E-04 0.505 -1.780 7.53E-03 0.333
GO:0002526 acute inflammatory response 220 2.600 1.08E-04 0.558 -3.092 1.28E-04 0.379
GO:0002573 myeloid leukocyte differentiation 204 1.656 4.97E-03 0.497 -1.541 4.46E-02 0.344
GO:0006364 rRNA processing 214 -1.717 1.13E-03 0.420 2.183 1.28E-04 0.419
GO:0006614
SRP-dependent cotranslational protein targeting to 
membrane 105 -2.113 1.09E-04 0.611 2.746 1.28E-04 0.704
GO:0006890 retrograde vesicle-mediated transport, Golgi to ER 86 1.818 4.72E-03 0.455 -1.947 1.13E-03 0.418
GO:0007033 vacuole organization 163 2.177 1.08E-04 0.459 -1.619 1.96E-02 0.355
GO:0008037 cell recognition 215 2.040 1.76E-04 0.535 -2.611 1.28E-04 0.328
GO:0009451 RNA modification 163 -1.523 3.29E-02 0.264 1.829 2.97E-04 0.294
GO:0010324 membrane invagination 135 2.441 1.08E-04 0.701 -2.837 1.28E-04 0.418
GO:0016052 carbohydrate catabolic process 199 2.129 1.08E-04 0.393 -1.605 1.83E-02 0.304
GO:0016236 macroautophagy 295 2.152 1.08E-04 0.432 -1.572 5.07E-03 0.365
GO:0019083 viral transcription 177 -1.732 1.32E-03 0.465 2.439 1.28E-04 0.494
GO:0019882 antigen processing and presentation 226 2.494 1.08E-04 0.475 -1.972 1.28E-04 0.369
GO:0022618 ribonucleoprotein complex assembly 277 -1.471 2.36E-02 0.294 1.576 5.06E-03 0.399
GO:0030100 regulation of endocytosis 281 1.998 1.08E-04 0.477 -1.544 2.21E-02 0.393
GO:0032635 interleukin-6 production 161 1.859 4.99E-04 0.505 -1.728 7.78E-03 0.427
GO:0032868 response to insulin 272 1.641 2.93E-03 0.402 -1.559 1.65E-02 0.335
GO:0034976 response to endoplasmic reticulum stress 285 1.564 5.95E-03 0.416 -1.592 5.17E-03 0.243
GO:0038093 Fc receptor signaling pathway 241 2.466 1.08E-04 0.524 -3.021 1.28E-04 0.371
GO:0038094 Fc-gamma receptor signaling pathway 142 2.607 1.08E-04 0.642 -3.182 1.28E-04 0.531
GO:0044839 cell cycle G2/M phase transition 266 1.740 3.08E-04 0.379 -1.618 3.86E-03 0.238
GO:0045132 meiotic chromosome segregation 90 1.738 2.60E-02 0.234 -1.902 6.60E-03 0.235
GO:0045730 respiratory burst 37 1.930 9.65E-03 0.552 -1.824 3.50E-02 0.469
GO:0048771 tissue remodeling 179 1.894 5.85E-04 0.505 -1.613 4.39E-02 0.367
GO:0050764 regulation of phagocytosis 98 1.880 1.87E-03 0.547 -1.748 2.09E-02 0.468
GO:0050864 regulation of B cell activation 184 1.949 1.08E-04 0.500 -2.765 1.28E-04 0.326
GO:0051225 spindle assembly 108 1.833 1.87E-03 0.284 -2.041 1.28E-04 0.443
GO:0051262 protein tetramerization 172 1.812 1.12E-03 0.311 -1.699 7.51E-03 0.248
GO:0051304 chromosome separation 90 1.965 5.85E-04 0.267 -2.215 1.28E-04 0.297
GO:0051321 meiotic cell cycle 249 1.596 1.30E-02 0.275 -1.721 3.60E-03 0.188
GO:0051701 interaction with host 209 1.707 1.64E-03 0.416 -1.602 1.52E-02 0.297
GO:0051965 positive regulation of synapse assembly 68 -1.788 4.36E-02 0.650 1.794 3.69E-02 0.364
GO:0051984 positive regulation of chromosome segregation 28 1.864 2.02E-02 0.240 -1.825 4.01E-02 0.346
GO:0061640 cytoskeleton-dependent cytokinesis 100 1.688 2.03E-02 0.417 -1.763 1.37E-02 0.314
GO:0070125 mitochondrial translational elongation 88 1.613 3.33E-02 0.481 1.892 1.60E-03 0.322
GO:0071216 cellular response to biotic stimulus 236 1.756 8.42E-04 0.421 -1.529 3.86E-02 0.385
GO:0140014 mitotic nuclear division 264 1.766 1.76E-04 0.227 -2.222 1.28E-04 0.394
GO:1901216 positive regulation of neuron death 94 1.742 1.08E-02 0.533 -1.930 1.54E-03 0.382
GO:1901988 negative regulation of cell cycle phase transition 267 1.757 3.65E-04 0.432 -1.811 1.28E-04 0.295
GO:1902850 microtubule cytoskeleton organization involved in mitosis 131 1.891 4.99E-04 0.330 -2.213 1.28E-04 0.461
GO:1904668 positive regulation of ubiquitin protein ligase activity 12 1.889 2.05E-02 0.545 -1.835 3.60E-02 0.273
GO:1905819 negative regulation of chromosome separation 40 1.704 4.89E-02 0.324 -2.197 1.92E-04 0.382
Legend
ID GO term ID
Size
Number of genes defining the biological process in the 
GO database 
NES COVID Normalize Enrichment Score for the COVID19 dataset
pCOVID FDR-corrected p-value
ratio COVID
Ratio between #enriched genes and #total genes in 
biological process
NES RA AbataceptNormalize Enrichment Score for the abatacept dataset
pABT FDR-corrected p-value
ratio ABT
Ratio between #enriched genes and #total genes in 
biological process
